Dermorphin decreases plasma LH levels in human: evidence for a modulatory role of gonadal steroids.

Petraglia F, Degli Uberti EC, Trasforini G, Facchinetti F, Margutti A, Volpe A, Salvadori S, Tomatis R, Genazzani AR

Peptides1 Sept 1985Cited by 6 (Europe PMC)

PMID3936026DOI10.1016/0196-9781(85)90317-1PepBankPUB-03936026

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In fertile women, dermorphin significantly decreased plasma LH versus baseline and placebo values.
In plain wordsIn fertile women, dermorphin reduced plasma LH compared with baseline and placebo.
Peptide
Dermorphin
Outcome
DecreasePlasma LH in fertile women
Study
n: not reported in source
Comparator
baseline and placebo values
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5.5 micrograms/kg min · infusion · 30 minAs given in this study (human).
Source sentences
Summary
In fertile subjects, dermorphin (5.5 micrograms/kg min for 30 min) decreases plasma LH (p less than 0.01 vs. baseline and placebo values), but not plasma FSH.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602602
02HumanNon-randomized trialEfficacy outcome
In fertile women, dermorphin did not decrease plasma FSH.
In plain wordsIn fertile women, dermorphin did not decrease plasma FSH.
Peptide
Dermorphin
Outcome
No significant changePlasma FSH in fertile women
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5.5 micrograms/kg min · infusion · 30 minAs given in this study (human).
Source sentences
Summary
In fertile subjects, dermorphin (5.5 micrograms/kg min for 30 min) decreases plasma LH (p less than 0.01 vs. baseline and placebo values), but not plasma FSH.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602603
03HumanNon-randomized trialEfficacy outcome
In fertile women, LH area under the curve during dermorphin infusion was significantly lower than during placebo infusion.
In plain wordsIn fertile women, LH area under the curve was lower with dermorphin than placebo infusion.
Peptide
Dermorphin
Outcome
DecreaseLH area under the curve
Study
n: not reported in source
Comparator
placebo infusion
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
5.5 micrograms/kg min · infusion · 30 minAs given in this study (human).
Source sentences
Summary
The area under the curve during dermorphin infusion was significantly lower than during placebo infusion (p less than 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602604
04HumanNon-randomized trialEfficacy outcome
In untreated postmenopausal women, dermorphin did not significantly modify plasma LH.
In plain wordsIn untreated postmenopausal women, dermorphin did not significantly change plasma LH.
Peptide
Dermorphin
Outcome
No significant changePlasma LH in untreated postmenopausal women
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
In postmenopausal women not subjected to any treatment, dermorphin infusion did not significantly modify plasma LH and FSH levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602605
05HumanNon-randomized trialEfficacy outcome
In untreated postmenopausal women, dermorphin did not significantly modify plasma FSH.
In plain wordsIn untreated postmenopausal women, dermorphin did not significantly change plasma FSH.
Peptide
Dermorphin
Outcome
No significant changePlasma FSH in untreated postmenopausal women
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
In postmenopausal women not subjected to any treatment, dermorphin infusion did not significantly modify plasma LH and FSH levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602606
06HumanNon-randomized trialEfficacy outcome
In postmenopausal women treated with conjugated estrogens and medroxyprogesterone acetate, dermorphin significantly decreased plasma LH versus baseline and placebo values.
In plain wordsIn steroid-treated postmenopausal women, dermorphin reduced plasma LH compared with baseline and placebo.
Peptide
Dermorphin
Outcome
DecreasePlasma LH in steroid-treated postmenopausal women
Study
n: not reported in source
Comparator
baseline and placebo values
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
On the contrary, its administration to postmenopausal subjects treated with conjugated estrogens and medroxyprogesterone acetate significantly decreased plasma LH levels (p less than 0.01, vs. baseline, placebo and area under the curve).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women.
Report a problemFND-0393602608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.